AVANIR Pharmaceuticals Invites Investors to Listen to the Thinkequity Partners 4th Annual Growth Conference Webcast

San Diego, August 23, 2006 -- AVANIR Pharmaceuticals (NASDAQ: AVNR) will be presenting at the ThinkEquity Partners 4th Annual Growth Conference on Tuesday, September 12, 2006 at 1:30 p.m. PDT in San Francisco, California.  AVANIR's President and Chief Executive Officer, Eric K. Brandt, will be presenting at the investor conference.
The presentation will be available via a live webcast accessible through AVANIR's corporate website at www.avanir.com.  To access the webcast, log on to AVANIR's site fifteen minutes prior to the presentation to register and download any necessary audio software.  An archive of the presentation will be available for 90 days following the event. 

AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.  AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases.  AVANIR currently markets FazaClo®, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments.  FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder.  For full prescribing information and important safety information regarding FazaClo, please visit
www.fazaclo.com  AVANIR's lead product candidate, Neurodex™ for the treatment of involuntary emotional expression disorder, is the subject of a New Drug Application under priority review with the FDA.  Additionally, AVANIR has initiated a Phase III clinical trial with Neurodex as a potential treatment for patients with painful diabetic neuropathy.  AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease.  The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.  Further information about AVANIR can be found at www.avanir.com.

AVANIR Pharmaceuticals Contacts:

Patrick O'Brien   

Patrice Saxon

Aug 23, 2006